ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
NEW YORK, Jan. 29, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased GW Pharmaceuticals plc (Nasdaq:GWPH) securities between December 4, 2014 and January 8, 2016.
Click here to learn about the case: http://docs.wongesq.com/GWPH-Info-Request-Form-1080. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company lacked effective internal financial controls; (ii) the Company lacked effective controls over completeness and valuation of clinical trial accruals; and (iii) as a result of the foregoing, Defendants’ statements about GW Pharmaceuticals’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
In its 2015 Annual Report, GW Pharmaceuticals disclosed the discovery of a material weakness in its internal control over financial reporting for the year ended September 30, 2015. The Company noted that “management does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies.” On this news, GW Pharmaceuticals stock fell $3.55, or nearly 6%, to close at $56.31 per share on January 11, 2016.
If you suffered a loss in GW Pharmaceuticals you have until March 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/GWPH-Info-Request-Form-1080.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
